Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Dexcom (DXCM) Shares Repurchased (2023 - 2025)

Dexcom has reported Shares Repurchased over the past 3 years, most recently at $312.8 million for Q4 2025.

  • Quarterly Shares Repurchased changed N/A to $312.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, changed 0.0% year-over-year, with the annual reading at $500.0 million for FY2025, 33.33% down from the prior year.
  • Shares Repurchased was $312.8 million for Q4 2025 at Dexcom, up from $187.2 million in the prior quarter.
  • Over five years, Shares Repurchased peaked at $750.0 million in Q3 2024 and troughed at $187.2 million in Q3 2025.
  • The 3-year median for Shares Repurchased is $406.4 million (2023), against an average of $437.5 million.
  • The largest YoY upside for Shares Repurchased was 75.04% in 2025 against a maximum downside of 75.04% in 2025.
  • A 3-year view of Shares Repurchased shows it stood at $500.0 million in 2023, then soared by 50.0% to $750.0 million in 2024, then plummeted by 58.29% to $312.8 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Shares Repurchased are $312.8 million (Q4 2025), $187.2 million (Q3 2025), and $750.0 million (Q3 2024).